TrialLung cancer (Amsterdam, Netherlands)2014

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.

Julian R Molina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.